Few researchers from the Cancer Institute of New Jersey have discovered candidate drugs, which have the potential to restrict an essential protein which is accountable for growth of acute tumor, might be doing the exact opposite. The study will be presented in the 101st Annual Meeting of the American Association for Cancer Research in Washington, D. C.

In order to treat prostate cancer, the doctors follow surgeries or radiation therapies along with the recommendation of the few drugs to halt the tumor, but the researchers have been trying to explore other alternatives to treat prostate cancer.

Many continuous researches have established that tumor growth is produced by a set of cells which later on give rise to the large sized tumor. The cells are called tumor initiating cells or cancer stem cells which resist chemotherapy.

The study resulted in the detection of sub-fractions of prostate tumor cells which led to the birth of tumors in zebra fish or any other models. The novel little molecule called Bmi-1 inhibitors was provided by Dr. Thomas Davis.

Collaboration among the various CINJ laboratories of Drs. Joseph R. Bertino, Robert S. DiPaola, Daniel Medina and Hatem Sabaawy was done in order to carry on with the research successfully.